Press

MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials

May 3 • 6 min read

VANCOUVER, BC / ACCESSWIRE / April 30, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the “Company” or “MindBio“), a clinical stage biopharma company developing innovative psychiatric treatments using microdoses of psychedelic medicines to revolutionize mental health treatments, is delighted to announce the regulatory approval of a series of clinical trials in women’s health using MB22001, a proprietary titratable…

PharmaDrug Announces Director Appointment and Resignation

May 3 • 3 min read

Toronto, Ontario–(Newsfile Corp. – May 2, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce today the appointment of Zalman Goldman to the board…

Awakn Life Sciences Discusses Filing of Financial Statements

May 3 • 3 min read

Toronto, Ontario–(Newsfile Corp. – May 2, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that, it intends to file its audited annual financial statements and MD&A for the…

Mydecine Receives Management Cease Trade Order

May 3 • 3 min read

VANCOUVER, British Columbia, May 2, 2024 (TheNewswire) — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has received a temporary Management Cease Trade Order (“MCTO”) on April 26, 2024, under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”) from the British Columbia Securities Commission (“BCSC”) in connection with the Company’s filing of its audited annual…

PharmaDrug’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

May 2 • 3 min read

Toronto, Ontario–(Newsfile Corp. – May 1, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441